US Clinical Labs To Lose Money On COVID-19 Testing Without $5Bn Set Aside In Third $1Tn Aid Bill
A $5bn emergency fund reimbursing US clinical laboratories for scaling up COVID-19 testing with lab-developed tests must be part of a $1tn Senate coronavirus aid and relief package, clinical lab group ACLA says. Other provisions already included in the draft bill address stockpiling of testing swabs, liability protection for medtech firms, a requirement for device makers to report supply chain shortages, the expanded use of telehealth, and preventing durable medical equipment payment reductions.
You may also be interested in...
The US Department of Health and Human Services is offering some legal protection to developers of devices and diagnostics for use in the fight against the novel coronavirus.
The US FDA on 29 February issued a new guidance giving the OK to labs with pending COVID-19 laboratory-developed tests (LDTs) to use them while they await the agency’s approval under Emergency Use Authorization. The agency issued the guidance quickly, taking the unusual step of forgoing a public comment period.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.